The BBC3 Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the Ca Ski cervical carcinoma line. This format provides a heterogeneous pool of cells with disrupted BBC3 alleles, avoiding clonal selection artifacts. The knockout pool facilitates loss-of-function studies of BBC3 in apoptotic signaling without single-cell cloning bottlenecks. Researchers employ these cells as a modular platform for dissecting BBC3-dependent apoptotic pathways under physiologically heterogeneous conditions.
Ca Ski cells originate from a cervical cancer metastasis and carry integrated HPV16 DNA, leading to E6-mediated TP53 degradation and E7-driven cell cycle dysregulation. This line is a standard model for HPV-positive cervical squamous cell carcinoma, particularly suited to study viral oncoprotein interactions with host apoptosis pathways. First established from a small intestine metastatic site, Ca Ski cells retain key tumor features and remain a cornerstone in cervical cancer research.
BBC3 (PUMA) is a BH3-only protein that promotes apoptosis by inhibiting anti-apoptotic BCL-2 family members. Transcriptionally induced by TP53, E2F1, FOXO3, MYC, and TP73, BBC3 binds and neutralizes BCL2, BCL2L1, MCL1, BCL2A1, and BCL2L2, freeing BAX and BAK1 to permeabilize mitochondria. This triggers cytochrome c release, APAF1-driven apoptosome assembly, and caspase-9/3 activation. Disruption of BBC3 uncouples intrinsic apoptosis regulation, enabling precise dissection of p53-dependent and independent death signals. Given its central position at the intersection of DNA damage sensing and cell death execution, BBC3 serves as a critical node for studying therapeutic apoptosis engagement.
In Ca Ski cells with impaired p53, residual apoptosis relies on alternative BBC3 regulation, making this knockout crucial for understanding HPV-induced apoptotic evasions. Eliminating BBC3 reveals contributions to drug sensitivity and helps map compensatory mechanisms. This model is particularly informative when analyzing the efficacy of agents like cisplatin or etoposide that trigger apoptosis via mitochondrial pathways, and it enables identification of synthetic lethal interactions that could be exploited therapeutically in HPV-driven cancers. The polyclonal nature mirrors tumor heterogeneity, offering a robust model for translational cervical cancer studies.
Applications include investigation of p53-mediated and intrinsic apoptosis, chemotherapy response profiling, and HPV oncogenesis research. Compatible assays encompass western blotting, RT-qPCR, Annexin V staining, caspase-3/7 activity, MTT viability, JC-1 mitochondrial membrane potential, and cytochrome c release assays. Additionally, the polyclonal knockout cells can be used in co-culture experiments to study bystander effects in tumor microenvironments or in high-throughput screening formats to identify novel modulators of the intrinsic apoptosis pathway. For further information, custom knockout generation, or technical support, please contact Ascent Research.
